Skip to main content
Erschienen in: Current Dermatology Reports 4/2022

05.08.2022 | Hospital-Based Dermatology (L Guggina and C Nguyen, Section Editors)

Inpatient Considerations in the Diagnosis and Management of the Cutaneous T-Cell Lymphoma Patient

verfasst von: Samantha Jakuboski, Thomas Doyle, Marianne Tawa, David C. Fisher, Nicole LeBoeuf, Cecilia Larocca

Erschienen in: Current Dermatology Reports | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

To review when to consider a diagnosis of cutaneous T-cell lymphoma (CTCL) in the inpatient setting and the diagnostic approach, as well as complications of disease and treatment that could lead to hospitalization.

Recent Findings

Cutaneous T-cell lymphomas (CTCLs) are a diverse group of non-Hodgkin lymphomas that are difficult to diagnosis as the initial presentation can mimic other benign inflammatory or infectious conditions of the skin. While the clinical course is typically indolent, with most cases normally diagnosed and managed in the outpatient settings, some CTCL-associated clinical scenarios, including infections, treatment-related toxicity/side effects, hemophagocytic lymphohistiocytosis (HLH), or spread to extra-cutaneous organs, warrant management in the inpatient setting.

Summary

Early involvement of dermatology specialists is critical for recognizing and diagnosing CTCL in a timely matter, managing treatments and their toxicities, and for improving both morbidity and mortality in patients.
Literatur
1.
Zurück zum Zitat Larocca C, Kupper T. Mycosis fungoides and Sezary syndrome: an update. Hematol Oncol Clin North Am. 2019;33(1):103–20.CrossRef Larocca C, Kupper T. Mycosis fungoides and Sezary syndrome: an update. Hematol Oncol Clin North Am. 2019;33(1):103–20.CrossRef
2.
Zurück zum Zitat • Kirsch IR, Watanabe R, O'Malley JT, et al. TCR sequencing facilitates diagnosis and identifies mature T cells as the cell of origin in CTCL. Sci Transl Med. 2015;7(308):308ra158. The study demonstrated the success of and introduces high-throughput TCR sequencing as an accurate diagnostic tool for CTCL in all stages and provided insights into the CTCL cell of origin and location. • Kirsch IR, Watanabe R, O'Malley JT, et al. TCR sequencing facilitates diagnosis and identifies mature T cells as the cell of origin in CTCL. Sci Transl Med. 2015;7(308):308ra158. The study demonstrated the success of and introduces high-throughput TCR sequencing as an accurate diagnostic tool for CTCL in all stages and provided insights into the CTCL cell of origin and location.
3.
Zurück zum Zitat Jackow CM, et al. Association of erythrodermic cutaneous T-cell lymphoma, superantigen-positive Staphylococcus aureus, and oligoclonal T-cell receptor V beta gene expansion. Blood. 1997;89(1):32–40.CrossRef Jackow CM, et al. Association of erythrodermic cutaneous T-cell lymphoma, superantigen-positive Staphylococcus aureus, and oligoclonal T-cell receptor V beta gene expansion. Blood. 1997;89(1):32–40.CrossRef
4.
Zurück zum Zitat van Doorn R, et al. Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients. Arch Dermatol. 2000;136(4):504–10. van Doorn R, et al. Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients. Arch Dermatol. 2000;136(4):504–10.
5.
Zurück zum Zitat • Larocca CA, LeBoeuf NR. Overview of cutaneous T-cell lymphomas. Hematol Oncol Clin North Am. 2019;33(4):669–686. Literature review on mycosis fungoides and sézary syndrome. • Larocca CA, LeBoeuf NR. Overview of cutaneous T-cell lymphomas. Hematol Oncol Clin North Am. 2019;33(4):669–686. Literature review on mycosis fungoides and sézary syndrome.
6.
Zurück zum Zitat Semaan S, et al. A clinician’s guide to cutaneous T-cell lymphoma presenting as recalcitrant eczematous dermatitis in adults. Int J Womens Dermatol. 2021;7(4):422–7.CrossRef Semaan S, et al. A clinician’s guide to cutaneous T-cell lymphoma presenting as recalcitrant eczematous dermatitis in adults. Int J Womens Dermatol. 2021;7(4):422–7.CrossRef
7.
Zurück zum Zitat Martinez-Escala ME, et al. Progression of undiagnosed cutaneous lymphoma after anti-tumor necrosis factor-alpha therapy. J Am Acad Dermatol. 2018;78(6):1068–76.CrossRef Martinez-Escala ME, et al. Progression of undiagnosed cutaneous lymphoma after anti-tumor necrosis factor-alpha therapy. J Am Acad Dermatol. 2018;78(6):1068–76.CrossRef
8.
Zurück zum Zitat Marks J. Erythroderma and its management. Clin Exp Dermatol. 1982;7(4):415–22.CrossRef Marks J. Erythroderma and its management. Clin Exp Dermatol. 1982;7(4):415–22.CrossRef
9.
Zurück zum Zitat Andersen RM, Thyssen JP, Maibach HI. The role of wet wrap therapy in skin disorders - a literature review. Acta Derm Venereol. 2015;95(8):933–9.CrossRef Andersen RM, Thyssen JP, Maibach HI. The role of wet wrap therapy in skin disorders - a literature review. Acta Derm Venereol. 2015;95(8):933–9.CrossRef
10.
Zurück zum Zitat Pielop JA, Jones D, Duvic M. Transient CD30+ nodal transformation of cutaneous T-cell lymphoma associated with cyclosporine treatment. Int J Dermatol. 2001;40(8):505–11.CrossRef Pielop JA, Jones D, Duvic M. Transient CD30+ nodal transformation of cutaneous T-cell lymphoma associated with cyclosporine treatment. Int J Dermatol. 2001;40(8):505–11.CrossRef
11.
Zurück zum Zitat Botella-Estrada R, et al. Erythroderma. A clinicopathological study of 56 cases. Arch Dermatol. 1994;130(12):1503–7. Botella-Estrada R, et al. Erythroderma. A clinicopathological study of 56 cases. Arch Dermatol. 1994;130(12):1503–7.
12.
Zurück zum Zitat Olsen EA, et al. Sezary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). J Am Acad Dermatol. 2011;64(2):352–404.CrossRef Olsen EA, et al. Sezary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). J Am Acad Dermatol. 2011;64(2):352–404.CrossRef
13.
Zurück zum Zitat Axelrod PI, Lorber B, Vonderheid EC. Infections complicating mycosis fungoides and Sezary syndrome. JAMA. 1992;267(10):1354–8.CrossRef Axelrod PI, Lorber B, Vonderheid EC. Infections complicating mycosis fungoides and Sezary syndrome. JAMA. 1992;267(10):1354–8.CrossRef
14.
Zurück zum Zitat Tsambiras PE, et al. Infectious complications of cutaneous t-cell lymphoma. Cancer Control. 2001;8(2):185–8.CrossRef Tsambiras PE, et al. Infectious complications of cutaneous t-cell lymphoma. Cancer Control. 2001;8(2):185–8.CrossRef
15.
Zurück zum Zitat Tokura Y, et al. Cutaneous colonization with staphylococci influences the disease activity of Sezary syndrome: a potential role for bacterial superantigens. Br J Dermatol. 1995;133(1):6–12.CrossRef Tokura Y, et al. Cutaneous colonization with staphylococci influences the disease activity of Sezary syndrome: a potential role for bacterial superantigens. Br J Dermatol. 1995;133(1):6–12.CrossRef
16.
Zurück zum Zitat Tokura Y, et al. Stimulation of cutaneous T-cell lymphoma cells with superantigenic staphylococcal toxins. J Invest Dermatol. 1992;98(1):33–7.CrossRef Tokura Y, et al. Stimulation of cutaneous T-cell lymphoma cells with superantigenic staphylococcal toxins. J Invest Dermatol. 1992;98(1):33–7.CrossRef
17.
Zurück zum Zitat Knaak C, et al. Treatment and mortality of hemophagocytic lymphohistiocytosis in adult critically Ill patients: a systematic review with pooled analysis. Crit Care Med. 2020;48(11):e1137–46.CrossRef Knaak C, et al. Treatment and mortality of hemophagocytic lymphohistiocytosis in adult critically Ill patients: a systematic review with pooled analysis. Crit Care Med. 2020;48(11):e1137–46.CrossRef
18.
Zurück zum Zitat Janka GE, Lehmberg K. Hemophagocytic lymphohistiocytosis: pathogenesis and treatment. Hematology Am Soc Hematol Educ Program. 2013;2013:605–11.CrossRef Janka GE, Lehmberg K. Hemophagocytic lymphohistiocytosis: pathogenesis and treatment. Hematology Am Soc Hematol Educ Program. 2013;2013:605–11.CrossRef
19.
Zurück zum Zitat Mehta RS, Smith RE. Hemophagocytic lymphohistiocytosis (HLH): a review of literature. Med Oncol. 2013;30(4):740.CrossRef Mehta RS, Smith RE. Hemophagocytic lymphohistiocytosis (HLH): a review of literature. Med Oncol. 2013;30(4):740.CrossRef
20.
Zurück zum Zitat Filipovich A, McClain K, Grom A. Histiocytic disorders: recent insights into pathophysiology and practical guidelines. Biol Blood Marrow Transplant. 2010;16(1 Suppl):S82–9.CrossRef Filipovich A, McClain K, Grom A. Histiocytic disorders: recent insights into pathophysiology and practical guidelines. Biol Blood Marrow Transplant. 2010;16(1 Suppl):S82–9.CrossRef
21.
Zurück zum Zitat Fajgenbaum DC, June CH. Cytokine storm. N Engl J Med. 2020;383(23):2255–73.CrossRef Fajgenbaum DC, June CH. Cytokine storm. N Engl J Med. 2020;383(23):2255–73.CrossRef
22.
Zurück zum Zitat Lee DE, et al. Hemophagocytic lymphohistiocytosis in cutaneous T-cell lymphoma. JAMA Dermatol. 2018;154(7):828–31.CrossRef Lee DE, et al. Hemophagocytic lymphohistiocytosis in cutaneous T-cell lymphoma. JAMA Dermatol. 2018;154(7):828–31.CrossRef
23.
Zurück zum Zitat Fardet L, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014;66(9):2613–20.CrossRef Fardet L, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014;66(9):2613–20.CrossRef
24.
Zurück zum Zitat Henter JI, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124–31.CrossRef Henter JI, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124–31.CrossRef
25.
Zurück zum Zitat Jordan MB, et al. How I treat hemophagocytic lymphohistiocytosis. Blood. 2011;118(15):4041–52.CrossRef Jordan MB, et al. How I treat hemophagocytic lymphohistiocytosis. Blood. 2011;118(15):4041–52.CrossRef
26.
Zurück zum Zitat Bergsten E, et al. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. Blood. 2017;130(25):2728–38.CrossRef Bergsten E, et al. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. Blood. 2017;130(25):2728–38.CrossRef
27.
Zurück zum Zitat Marsh RA, et al. Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab. Pediatr Blood Cancer. 2013;60(1):101–9.CrossRef Marsh RA, et al. Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab. Pediatr Blood Cancer. 2013;60(1):101–9.CrossRef
28.
Zurück zum Zitat Maschalidi S, et al. Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice. Blood. 2016;128(1):60–71.CrossRef Maschalidi S, et al. Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice. Blood. 2016;128(1):60–71.CrossRef
29.
Zurück zum Zitat Henter JI, et al. Hypercytokinemia in familial hemophagocytic lymphohistiocytosis. Blood. 1991;78(11):2918–22.CrossRef Henter JI, et al. Hypercytokinemia in familial hemophagocytic lymphohistiocytosis. Blood. 1991;78(11):2918–22.CrossRef
30.
Zurück zum Zitat Yu JT, et al. Reduced intensity conditioning allogeneic hematopoietic stem cell transplant could be beneficial to angioimmunoblastic T-cell lymphoma patients with hemophagocytic lymphohistiocytosis. Ann Hematol. 2012;91(5):805–7.CrossRef Yu JT, et al. Reduced intensity conditioning allogeneic hematopoietic stem cell transplant could be beneficial to angioimmunoblastic T-cell lymphoma patients with hemophagocytic lymphohistiocytosis. Ann Hematol. 2012;91(5):805–7.CrossRef
31.
Zurück zum Zitat Baser S, et al. Pulmonary manifestations in patients with cutaneous T-cell lymphomas. Cancer. 2007;109(8):1550–5.CrossRef Baser S, et al. Pulmonary manifestations in patients with cutaneous T-cell lymphomas. Cancer. 2007;109(8):1550–5.CrossRef
32.
Zurück zum Zitat Stein M, et al. Central neurologic involvement in mycosis fungoides: ten cases, actuarial risk assessment, and predictive factors. Cancer J. 2006;12(1):55–62.CrossRef Stein M, et al. Central neurologic involvement in mycosis fungoides: ten cases, actuarial risk assessment, and predictive factors. Cancer J. 2006;12(1):55–62.CrossRef
33.
Zurück zum Zitat Zhao G, et al. Central nervous system involvement in cutaneous T-cell lymphoma: 2 illustrative cases and a review of current literature. Clin Lymphoma Myeloma Leuk. 2014;14(1):e25-30.CrossRef Zhao G, et al. Central nervous system involvement in cutaneous T-cell lymphoma: 2 illustrative cases and a review of current literature. Clin Lymphoma Myeloma Leuk. 2014;14(1):e25-30.CrossRef
34.
Zurück zum Zitat Vu BA, Duvic M. Central nervous system involvement in patients with mycosis fungoides and cutaneous large-cell transformation. J Am Acad Dermatol. 2008;59(2 Suppl 1):S16-22.CrossRef Vu BA, Duvic M. Central nervous system involvement in patients with mycosis fungoides and cutaneous large-cell transformation. J Am Acad Dermatol. 2008;59(2 Suppl 1):S16-22.CrossRef
35.
Zurück zum Zitat Duarte RF, et al. Long-term outcome of allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sezary syndrome: a European society for blood and marrow transplantation lymphoma working party extended analysis. J Clin Oncol. 2014;32(29):3347–8.CrossRef Duarte RF, et al. Long-term outcome of allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sezary syndrome: a European society for blood and marrow transplantation lymphoma working party extended analysis. J Clin Oncol. 2014;32(29):3347–8.CrossRef
36.
Zurück zum Zitat Foss FM. DAB(389)IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma. Clin Lymphoma 2000;1(2):110–6, discussion 117. Foss FM. DAB(389)IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma. Clin Lymphoma 2000;1(2):110–6, discussion 117.
37.
Zurück zum Zitat Ohmachi K, et al. E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma: a phase I study. Cancer Sci. 2018;109(3):794–802.CrossRef Ohmachi K, et al. E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma: a phase I study. Cancer Sci. 2018;109(3):794–802.CrossRef
38.
Zurück zum Zitat Kawai H, et al. Phase II study of E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma. Cancer Sci. 2021;112(6):2426–35.CrossRef Kawai H, et al. Phase II study of E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma. Cancer Sci. 2021;112(6):2426–35.CrossRef
39.
Zurück zum Zitat Duvic M, et al. Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. Blood. 2015;125(12):1883–9.CrossRef Duvic M, et al. Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. Blood. 2015;125(12):1883–9.CrossRef
40.
Zurück zum Zitat Kim YH, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018;19(9):1192–204.CrossRef Kim YH, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018;19(9):1192–204.CrossRef
41.
Zurück zum Zitat Larocca C, Kupper TS, LeBoeuf NR. Mogamulizumab forecast: clearer patients, with a slight chance of immune mayhem. Clin Cancer Res. 2019;25(24):7272–4.CrossRef Larocca C, Kupper TS, LeBoeuf NR. Mogamulizumab forecast: clearer patients, with a slight chance of immune mayhem. Clin Cancer Res. 2019;25(24):7272–4.CrossRef
42.
Zurück zum Zitat Chen L, et al. Mogamulizumab-associated cutaneous granulomatous drug eruption mimicking mycosis fungoides but possibly indicating durable clinical response. JAMA Dermatol. 2019;155(8):968–71.CrossRef Chen L, et al. Mogamulizumab-associated cutaneous granulomatous drug eruption mimicking mycosis fungoides but possibly indicating durable clinical response. JAMA Dermatol. 2019;155(8):968–71.CrossRef
43.
Zurück zum Zitat Kwan JM, et al. Mogamulizumab-associated acute myocarditis in a patient with T-cell lymphoma. JACC Case Rep. 2021;3(7):1018–23.CrossRef Kwan JM, et al. Mogamulizumab-associated acute myocarditis in a patient with T-cell lymphoma. JACC Case Rep. 2021;3(7):1018–23.CrossRef
44.
Zurück zum Zitat Larocca CA, TM, LeBoeuf N, Virgin C, Goyal A, Amato A, De Girolami U, McGrath CKE, Mullally W, Sparks J, Fisher DC, Kupper TS. Successful treatment of mogamulizumab-induced myositis. USCLC annual meeting. 2021. Larocca CA, TM, LeBoeuf N, Virgin C, Goyal A, Amato A, De Girolami U, McGrath CKE, Mullally W, Sparks J, Fisher DC, Kupper TS. Successful treatment of mogamulizumab-induced myositis. USCLC annual meeting. 2021.
45.
Zurück zum Zitat Roccuzzo G, et al. Immune check point inhibitors in primary cutaneous T-cell lymphomas: biologic rationale, clinical results and future perspectives. Front Oncol. 2021;11: 733770.CrossRef Roccuzzo G, et al. Immune check point inhibitors in primary cutaneous T-cell lymphomas: biologic rationale, clinical results and future perspectives. Front Oncol. 2021;11: 733770.CrossRef
46.
Zurück zum Zitat Lesokhin AM, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J Clin Oncol. 2016;34(23):2698–704.CrossRef Lesokhin AM, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J Clin Oncol. 2016;34(23):2698–704.CrossRef
47.
Zurück zum Zitat Khodadoust MS, et al. Pembrolizumab in relapsed and refractory mycosis fungoides and Sezary syndrome: a multicenter phase II study. J Clin Oncol. 2020;38(1):20–8.CrossRef Khodadoust MS, et al. Pembrolizumab in relapsed and refractory mycosis fungoides and Sezary syndrome: a multicenter phase II study. J Clin Oncol. 2020;38(1):20–8.CrossRef
48.
Zurück zum Zitat •• Weng WK, Arai S, Rezvani A, et al. Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma. Blood Adv. 2020;4(18):4474–4482. Pivotal clinical trial that showed allogeneic stem cell transplant to be an effective treatment in cutaneous T-cell lymphoma. •• Weng WK, Arai S, Rezvani A, et al. Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma. Blood Adv. 2020;4(18):4474–4482. Pivotal clinical trial that showed allogeneic stem cell transplant to be an effective treatment in cutaneous T-cell lymphoma.
49.
Zurück zum Zitat Divito SJ, et al. Peripheral host T cells survive hematopoietic stem cell transplantation and promote graft-versus-host disease. J Clin Invest. 2020;130(9):4624–36.CrossRef Divito SJ, et al. Peripheral host T cells survive hematopoietic stem cell transplantation and promote graft-versus-host disease. J Clin Invest. 2020;130(9):4624–36.CrossRef
50.
Zurück zum Zitat Foo SH, et al. Unmasking mycosis fungoides/Sezary syndrome from preceding or co-existing benign inflammatory dermatoses requiring systemic therapies: patients frequently present with advanced disease and have an aggressive clinical course. Br J Dermatol. 2016;174(4):901–4.CrossRef Foo SH, et al. Unmasking mycosis fungoides/Sezary syndrome from preceding or co-existing benign inflammatory dermatoses requiring systemic therapies: patients frequently present with advanced disease and have an aggressive clinical course. Br J Dermatol. 2016;174(4):901–4.CrossRef
51.
Zurück zum Zitat Weenig RH, et al. Fatal cytotoxic cutaneous lymphoma presenting as ulcerative psoriasis. Arch Dermatol. 2009;145(7):801–8.CrossRef Weenig RH, et al. Fatal cytotoxic cutaneous lymphoma presenting as ulcerative psoriasis. Arch Dermatol. 2009;145(7):801–8.CrossRef
Metadaten
Titel
Inpatient Considerations in the Diagnosis and Management of the Cutaneous T-Cell Lymphoma Patient
verfasst von
Samantha Jakuboski
Thomas Doyle
Marianne Tawa
David C. Fisher
Nicole LeBoeuf
Cecilia Larocca
Publikationsdatum
05.08.2022
Verlag
Springer US
Erschienen in
Current Dermatology Reports / Ausgabe 4/2022
Elektronische ISSN: 2162-4933
DOI
https://doi.org/10.1007/s13671-022-00367-4

Weitere Artikel der Ausgabe 4/2022

Current Dermatology Reports 4/2022 Zur Ausgabe

Hospital-Based Dermatology (L Guggina and C Nguyen, Section Editors)

SARS-CoV-2 Infection and Vaccination Cutaneous Manifestations for the Inpatient Dermatologist

Covid-19 in Dermatology (J. M. Gelfand, Section editor)

Viruses, Variants, and Vaccines: How COVID-19 Has Changed the Way We Look at Skin

Covid-19 in Dermatology (J. M. Gelfand, Section editor)

Outpatient Management of COVID-19: A Primer for the Dermatologist

Contact Dermatitis (B.Adler and V. Deleo, Section editors)

Contact Urticaria Syndrome: a Comprehensive Review

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Isotretinoin: Risiko für schwere Laboranomalien „marginal erhöht“

08.05.2024 Akne Nachrichten

Die Aknetherapie mit Isotretinoin kann einen Anstieg von Leberenzymen und Blutfetten verursachen. Das Risiko für schwere Störungen ist laut einer Forschungsgruppe der Universität Lübeck aber nur marginal erhöht und auf einen engen Zeitraum konzentriert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Klinik aktuell Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärztinnen und Psychotherapeuten.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.